Analysis

Newamsterdam Pharma Company N.v. (NAMS) Stock Analysis

Newamsterdam Pharma Company N.v. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to NAMS.

websiteNAMS/analysis/NAMS

Newamsterdam Pharma Company N.v.

Newamsterdam Pharma Company N.v. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to NAMS.

Stock profile

Ticker

NAMS

Asset type

Stock

Market cap

$3.55B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Newamsterdam Pharma Company N.v. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • NAMS primary listing
  • KH6
  • A3DUAC

Latest Newamsterdam Pharma Company N.v. news

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical ...

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical b...

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical...

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinde...

Research sections

Valuation

Review valuation context for Newamsterdam Pharma Company N.v..

Future growth

Review future growth context for Newamsterdam Pharma Company N.v..

Past performance

Review past performance context for Newamsterdam Pharma Company N.v..

Financial health

Review financial health context for Newamsterdam Pharma Company N.v..

Dividend

Review dividend context for Newamsterdam Pharma Company N.v..

Management

Review management context for Newamsterdam Pharma Company N.v..

Ownership

Review ownership context for Newamsterdam Pharma Company N.v..

Other information

Review other information context for Newamsterdam Pharma Company N.v..

Community

Review community context for Newamsterdam Pharma Company N.v..